Open Access Open Access  Restricted Access Subscription or Fee Access

Comparative Analysis of Ovarian Surface Epithelial Lesions with Corresponding Tubal Epithelial Changes with Reference to Ki67 and p53 Immunostains

Srijita Biswas, Debashis Chakrabarty

Abstract


Ovarian surface epithelial cancers have high mortality due to late presentation. The ovarian surface epithelial tumours originate from fallopian tubal epithelium. Hence, ovarian surface epithelial tumours have good correlation with respect to genetic and immunohistological changes of fallopian tubes, especially fimbrial end epithelium. These changes are evident long before significant morphological changes in the ovaries appear. p53 and Ki67 are two important proliferative markers, and useful to evaluate ovarian surface tumours. In the present study, 58 cases of total ovarian lesions and corresponding fallopian tubes were examined. About 37 were benign (63.79%) and 21 (36.20%) were malignant. All the cases were correlated with clinical, histopathological and immunostaining scoring following standard methods. Malignant cases correlated with both p53 and Ki67 (P value less than 0.0001 (significant), but benign cases correlated well with p53 only (significant as P value less than 0.001). p53 and Ki67 immunostaining with histopathological correlation of tubal epithelium may well indicate the malignant potential of ipsilateral ovarian surface lesions and in future may be included in cancer screening for ovarian surface epithelial tumours.

 

Keywords: Immunostaining, ovary, fallopian tube, histopathology

Cite this Article

S. Biswas, D. Chakrabarty, S.N. Banerjee, S. Mridha. Comparative analysis of ovarian surface epithelial lesions with corresponding tubal epithelial changes with reference to Ki67 and p53 immunostains. Research & Reviews: A Journal of Immunology. 2019; 9(2): 6–10p


Keywords


Key words : Immunostaining, ovary, fallopian tube, histopathology

Full Text:

PDF

References


• Holschneider CH , Berek JS. Ovarian cancer: epidemiology, biology,

and prognostic factors. SeminSurgOncol. 2000;19(1):3-10.

• World Health Organization. GLOBOCAN 2012: Estimated Cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/factsheet.asp (accessed 13 October, 2016).

• Juan Rosai. Female reproductive system. Juan Rosai, eds. In: Rosai and Ackerman's Surgical Pathology. 10th ed. Gurgaon: Mosby Elsevier; 2011: 1553-1609.

• Fletcher Zaloudek C F. Tumors of ovary. In Christopher D. M Fletcher MD, eds: Diagnostic histopathology of tumors. 2nd ed. Churchill Livingstone :Harcourt Publication Ltd;2000.

• Sieben NL, Kolkman-Uljee SM, Flanagan AM, Le Cessie S, Cleton-Jansen AM, Cornelisse CJ, Fleuren GJ: Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol 2003; 162:1095-1101.

• Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ,

Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol.2004;23:41–44. doi: 10.1097/01.pgp.0000101080.35393.16. [PubMed] [Cross Ref]

• Selvaggi SM. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Arch Pathol Lab Med. 2000;124:477. [PubMed]

• Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol.2001;25:1283–1289. doi: 10.1097/00000478-200110000-00009. [PubMed] [Cross Ref]

• Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J ClinOncol. 2005;23:127–132. [PubMed]

• Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J SurgPathol. 2006;30:230–236. doi: 10.1097/01.pas.0000180854.28831.77.[PubMed

• Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35. doi: 10.1002/path.2091. [PubMed] [Cross Ref]

• Lane DP. Cell immortalization and transformation by the p53 gene. Nature. 1984; 312(5995):596–7. [PubMed: 6095111]

• Linzer DI, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979; 17(1):43–52. [PubMed: 222475]

• Eliyahu D, Michalovitz D, Eliyahu S, et al. Wild-type p53 can inhibit oncogene-mediated focus formation. ProcNatlAcadSci USA. 1989; 86(22):8763–7. [PubMed: 2530586]

• Parada LF, Land H, Weinberg RA, et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 1984; 312(5995):649–51. [PubMed: 6390217]

• Jenkins JR, Rudge K, Currie GA. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature. 1984; 312(5995):651–4. [PubMed: 6095117]

• Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–908. [PubMed: 15838523]

• Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994; 54(9):2496–503. [PubMed: 7909277]

• P. Louopouls, J. R. Thornton, W. F. Robinson et al; clinical and pathological relevance of P53 index in canine osseous tumors; vet Pathol 40:237 – 248 (2003), 240.

• Shirendeb U, Hishikawa Y, Moriyama S, et al: Human papil-lomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. ActaHistochemCytochem 42: 181‑190, 2009

• Karamitopoulou E, Perentes E, Tolnay M and Probst A: Prognostic significance of MIB ‑1, p53, and bcl‑2 immunoreac-tivity in

meningiomas. Hum Pathol 29: 140‑145, 1998.

• McCormick D, Chong H, Hobbs C, et al.: Detection of the Ki‑67 antigen in fixed and wax‑embedded sections with the monoclonal antibody MIB‑1. Histopathology 22:355‑360, 1993.

• Xuhui Ma, Munteng Wu, Hao Song et al; Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastasis; J. Cancer 8(18)3828-3837, 2017, 3

• Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol.2001;25:1283–1289. doi: 10.1097/00000478-200110000-00009. [PubMed] [Cross Ref]

• Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J SurgPathol. 2007;31:161–169. doi: 10.1097/01.pas.0000213335.40358.47. [PubMed] [Cross Ref]

• Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J GynecolPathol. 2008;27:1–9. [PubMed]

• Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53:127–138. [PubMed]

• Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J SurgPathol. 2007;31:161–169. [PubMed]

• Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J SurgPathol. 2006;30:230–236. [PubMed]

• Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35. [PubMed]

• Vang R, Wheeler JE. Diseases of the fallopian tube and paratubal region. In: Kurman R, Ronnett B, Ellenson L, editors. Blaustein’s Pathology of the Female Genital Tract. 6. New York: Springer; (In Press)

• Agarwal P, Kulkarni DG, Chakrabarti PR, Chaurasia S, Dixit M, Gupta K. Clinicopathological Spectrum of Ovarian Tumors: A 5-Year Experience in a Tertiary Health Care Center. Journal of Basic and Clinical Reproductive Sciences, 2015;4(2).

• Malik I.A. A Prospective Study of Clinico-pathological Features of Epithelial Ovarian Cancer in Pakistan. JPMA 2002;52:155.

• Jha R, Karki S. Histological pattern of ovarian tumors and their age

distribution. Nepal Med Coll J. 2008 Jun;10(2):81-5.

• Bhattacharya M M, Shinde S D, Purandare V N. A clinicopathological analysis of 270 ovarian tumours. J Postgrad Med 1980;26:103.

• Lurie G, Wilkens L.R, Thompson P.J, Matsuno R K, Carney M E, Goodman M T. Symptom Presentation in Invasive Ovarian Carcinoma by Tumor Histological Type and Grade in a Multiethnic Population: A Case Analysis.GynecolOncol 2010 ; 119(2): 278-84.

• Sun M. A million dollars for the magic bullet. Science. 1981; 214(4527):1326–7. [PubMed: 7313689]

• Dickman S. ‘Gene of the year’ p53: when will it show clinical promise? Ann Oncol. 1993; 49:706–[PubMed: 8280648]

• Campbell S, Bhan V, Royston P, Whitehead M, Collins W. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989;299(6712):1363-1367

• Valentini A L, Gui B, Micco M, Mingote M C, De Gaetano, Ninivaggi, Bonomo L : Benign and Suspicious Ovarian Masses—MR Imaging Criteria for Characterization: Pictorial Review. J Oncol. 2012;2012:481806

• Smith EM, Anderson B. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 1985;56:2727

• Siddiqui RB, Shankar B, Khan IM. Morphological Patterns of Ovarian Neoplasms in Different Age Groups - A Center based study. P J M H S 2015;9(4): 1139

• J M, Kumar MP, Arora VS, Harish V, LA. Histopathological examination of primary ovarian tumors. Int J Res Health Sci [Internet] 2015;3(1):217-24.

• Ramachandran, G., Harilal K. R., Chinnamma, K. K and Thangavelu, H.: Ovarian neoplasms-a study of 903 cases. J. Obstet. and Gynec. India, 1972;22:309-15

• O’Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J SurgPathol. 2005;29:1034–1041. [PubMed]

• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–2303. [PubMed]

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. [PubMed]

• Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J HematolOncol. 2010;3:7. doi: 10.1186/1756-8722-3-7.[PMC free article] [PubMed] [Cross Ref]

• Sezik M, Ozkaya O, Demir F, Sezik HT, Kaya H. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. J ObstetGynaecol Res.2007;33:863–869. doi: 10.1111/j.1447-0756.2007.00669.x. [PubMed] [Cross Ref]


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Research & Reviews: A Journal of Immunology